On going treatment(s)-Chemotherapy Posts on Medivizor
Navigation Menu

On going treatment(s)-Chemotherapy Posts on Medivizor

How effective is a netupitant and palonosetron combination in preventing nausea and vomiting in patients with multiple myeloma?

How effective is a netupitant and palonosetron combination in preventing nausea and vomiting in patients with multiple myeloma?

Posted by on Sep 16, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study assessed the effectiveness of netupitant/palonosetron (NEPA; Akynzeo) in preventing nausea and vomiting in patients with multiple myeloma (MM) while receiving high-dose melphalan (HDM; Alkeran) and autologous stem cell transplantation (ASCT). The data showed that NEPA, without dexamethasone (DXM; Decadron), was...

Read More

How do bortezomib, thalidomide, dexamethasone and daratumumab impact the quality of life of patients with multiple myeloma?

How do bortezomib, thalidomide,  dexamethasone and daratumumab impact the quality of life of patients with multiple myeloma?

Posted by on Feb 26, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the health-related quality of life of patients with multiple myeloma (MM) after treatment with VTd (bortezomib, thalidomide, and dexamethasone) with or without daratumumab (D; Darzalex). The study found that all patients that received treatment had an improved quality of life, while...

Read More

Is stem cell transplant more effective than other treatments for multiple myeloma?

Is stem cell transplant more effective than other treatments for multiple myeloma?

Posted by on Feb 5, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study compared the effects of stem cell transplant to other newer treatments for recently diagnosed multiple myeloma (MM). The main finding was patients who received stem cell transplant had better outcomes than those who did not. Some background Stem cell transplant involves the transfer of cells to a patient. This is an effective...

Read More

What are the long-term outcomes following bendamustine treatment?

What are the long-term outcomes following bendamustine treatment?

Posted by on Mar 12, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study examined the long-term safety and effectiveness of bendamustine (Treanda) in lymphoma and leukemia. This study concluded that bendamustine is a safe and effective therapy for these patients. Some background Bendamustine has been shown to have high effectiveness and few side effects for a wide range of lymphomas. This drug is...

Read More

Does biosimilar filgrastim improve neutropenia in older DLBCL patients receiving chemotherapy?

Posted by on Dec 20, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study analyzed the outcomes of older patients with stage 3 or 4 DLBCL (diffuse large B-cell lymphoma) who received biosimilar filgrastim (Neupogen) during their chemotherapy. The study concluded that filgrastim was safe and effective in these patients. Some background Diffuse large B-cell lymphoma (DLBCL) is the most common type...

Read More

NHL with central nervous system involvement: Autologous stem cell transplant after high-dose chemotherapy an effective treatment option

NHL with central nervous system involvement: Autologous stem cell transplant after high-dose chemotherapy an effective treatment option

Posted by on Dec 12, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study examined outcomes of autologous stem cell transplants after high-dose chemotherapy in non-Hodgkin lymphoma (NHL) patients with central nervous system (CNS) involvement. This study reported durable remission and good disease control for NHL with CNS involvement.  Some background Many forms of NHL are treatable. When...

Read More

Using erythropoietin mouthwash to reduce the occurrence of oral mucositis in patients receiving autologous stem cell transplantation

Using erythropoietin mouthwash to reduce the occurrence of oral mucositis in patients receiving autologous stem cell transplantation

Posted by on Oct 7, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looked at how effective erythropoietin mouthwash was at preventing oral mucositis in cancer patients being treated with autologous stem cell transplantation. The study concluded that rinsing with erythropoietin mouthwash can prevent oral mucositis.  Some background Oral mucositis (OM) is a complication associated with...

Read More

Using erythropoietin mouthwash to reduce the occurrence of oral mucositis in patients receiving autologous stem cell transplantation

Using erythropoietin mouthwash to reduce the occurrence of oral mucositis in patients receiving autologous stem cell transplantation

Posted by on Oct 7, 2017 in Multiple Myeloma | 0 comments

In a nutshell This study looked at how effective erythropoietin mouthwash was at preventing oral mucositis in cancer patients being treated with autologous stem cell transplantation. The study concluded that rinsing with erythropoietin mouthwash can prevent oral mucositis.  Some background Oral mucositis (OM) is a complication associated with...

Read More

Long term outcomes for non-Hodgkin lymphoma patients treated with bendamustine

Posted by on Sep 14, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The authors looked at the outcomes for patients with non-Hodgkin lymphoma who were treated with bendamustine (Treanda). The authors concluded that bendamustine has good long-term outcomes for patients with non-Hodgkin lymphoma, especially when combined with rituximab (Rituxan).  Some background Bendamustine has long been a...

Read More

Adding ixazomib to treatment improves outcomes for relapsed/refractory multiple myeloma

Adding ixazomib to treatment improves outcomes for relapsed/refractory multiple myeloma

Posted by on May 29, 2017 in Multiple Myeloma | 0 comments

In a nutshell This study examined the safety and effectiveness of ixazomib (Ninlaro) when added to the treatment of relapsed multiple myeloma. Researchers concluded that ixazomib was safe and effective at improving treatment outcomes for relapsed multiple myeloma. Some background The addition of biologic drugs to standard treatment regimens for...

Read More